2026-2034年全球潛伏性結核感染檢測市場規模、佔有率、趨勢及成長分析報告

全球潛伏性結核病（LIT）感染檢測市場預計將從2025年的24億美元成長至2034年的40.8億美元，2026年至2034年的複合年成長率（CAGR）為6.08%。隨著醫療機構加大力度在感染發展為活動性結核病之前識別潛伏性結核病，該市場正經歷強勁成長。早期發現有助於及時進行預防性治療，控制疾病傳播，並有助於改善公共衛生狀況。全球對抗結核病的努力活性化、感染疾病預防意識的提高以及醫療篩檢計畫的擴展，都在推動已開發經濟體和新興經濟體採用先進的診斷技術。

醫療機構擴大採用干擾素釋放試驗、結核菌素皮膚試驗和先進的臨床檢測方法來提高篩檢的準確性和效率。免疫學檢測、自動化和數位化檢測系統的技術進步提高了診斷性能，同時縮短了檢測結果的報告時間。政府對結核病根除計畫的投入以及國際公共衛生合作持續推動市場擴張。對高危險群日益成長的關注也進一步刺激了市場需求。

前景依然十分樂觀，因為全球醫療衛生系統都將感染疾病預防和早期療育列為優先事項。攜帶式診斷平台、人工智慧（AI）驅動的臨床實驗室分析以及生物標記研究的進步將提高篩檢能力和可及性。醫療衛生基礎設施的擴建和對結核病研究的持續投入將創造巨大的商業機會。診斷技術的不斷創新將支持長期成長，並協助全球對抗結核病的努力。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球潛伏性結核感染檢測市場：依品牌分類

• 市場分析、洞察與預測
• QFT-Plus（QuantiFERON-TB Gold Plus）
• 其他

第5章 全球潛伏性結核感染檢測市場：依檢測方法分類

• 市場分析、洞察與預測
• 結核菌素皮膚試驗（TST）
• 干擾素-伽瑪釋放測試 (IGRA)

第6章 全球潛伏性結核感染檢測市場：依應用領域分類

• 市場分析、洞察與預測
• 與肺結核患者共同生活的家庭成員
• 感染愛滋病毒的人（PLHIV）
• 其他

第7章 全球潛伏性結核感染檢測市場：依最終用途分類

• 市場分析、洞察與預測
• 診斷檢查室
• 醫院和診所
• 學術和研究機構

第8章 全球潛伏性結核感染檢測市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • QIAGEN
  • BioMerieux
  • Oxford Immunotec
  • SD Biosensor Inc
  • Wantai BioPharm
  • Lionex GmbH
  • Serum Institute Of India
  • ARKRAY Inc
  • F. Hoffmann-La Roche
  • Abbott Laboratories
  • Siemens Healthineers
  • Danaher Corporation（Cepheid）
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Hologic
  • Revvity Inc
  • Fujirebio Holdings
  • Mylab Discovery Solutions

The global latent tuberculosis infection detection market size is expected to reach USD 4.08 Billion in 2034 from USD 2.40 Billion in 2025, growing at a CAGR of 6.08 during 2026-2034.This market is experiencing strong growth as healthcare organizations intensify efforts to identify latent tuberculosis infections before they progress to active disease. Early detection enables timely preventive treatment, helping reduce disease transmission and improve public health outcomes. Rising global tuberculosis control initiatives, increasing awareness of infectious disease prevention, and expanding healthcare screening programs are driving greater adoption of advanced diagnostic technologies across developed and emerging regions.

Healthcare providers are increasingly utilizing interferon-gamma release assays, tuberculin skin tests, and advanced laboratory diagnostics to improve screening accuracy and efficiency. Technological advancements in immunological testing, automation, and digital laboratory systems are enhancing diagnostic performance while reducing turnaround times. Government investments in tuberculosis elimination programs and international public health collaborations continue supporting market expansion. Growing focus on high-risk populations further strengthens demand.

The future outlook remains highly favorable as global healthcare systems prioritize infectious disease prevention and early intervention. Portable diagnostic platforms, artificial intelligence-assisted laboratory analysis, and improved biomarker research will enhance screening capabilities and accessibility. Expansion of healthcare infrastructure and continued investment in tuberculosis research will create significant opportunities. Ongoing innovation in diagnostic technologies will support long-term growth and contribute to global tuberculosis control efforts.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Brand

• QFT-Plus (QuantiFERON-TB Gold Plus)
• Others

By Test

• Tuberculin Skin Test (TST)
• Interferon Gamma Release Assay (IGRA)

By Application

• Household Contacts with Pulmonary TB
• People Living with HIV (PLHIV)
• Others

By End Use

• Diagnostic Laboratories
• Hospitals/Clinics
• Academic & Research Institutions

COMPANIES PROFILED

• QIAGEN, bioMerieux, Oxford Immunotec, SD Biosensor Inc., Wantai BioPharm, Lionex GmbH, Serum Institute of India, ARKRAY Inc., F. Hoffmann-La Roche, Abbott Laboratories, Siemens Healthineers, Danaher Corporation (Cepheid), Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic, Revvity Inc., Fujirebio Holdings, Mylab Discovery Solutions

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION MARKET: BY BRAND 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Brand
• 4.2. QFT-Plus (QuantiFERON-TB Gold Plus) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION MARKET: BY TEST 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Test
• 5.2. Tuberculin Skin Test (TST) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Interferon Gamma Release Assay (IGRA) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Household Contacts with Pulmonary TB Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. People Living with HIV (PLHIV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Hospitals/Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Academic & Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Brand
  • 8.2.2 By Test
  • 8.2.3 By Application
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Brand
  • 8.3.2 By Test
  • 8.3.3 By Application
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Brand
  • 8.4.2 By Test
  • 8.4.3 By Application
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Brand
  • 8.5.2 By Test
  • 8.5.3 By Application
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Brand
  • 8.6.2 By Test
  • 8.6.3 By Application
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL LATENT TUBERCULOSIS INFECTION DETECTION INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 QIAGEN
  • 10.2.2 BioMerieux
  • 10.2.3 Oxford Immunotec
  • 10.2.4 SD Biosensor Inc
  • 10.2.5 Wantai BioPharm
  • 10.2.6 Lionex GmbH
  • 10.2.7 Serum Institute Of India
  • 10.2.8 ARKRAY Inc
  • 10.2.9 F. Hoffmann-La Roche
  • 10.2.10 Abbott Laboratories
  • 10.2.11 Siemens Healthineers
  • 10.2.12 Danaher Corporation (Cepheid)
  • 10.2.13 Thermo Fisher Scientific
  • 10.2.14 Bio-Rad Laboratories
  • 10.2.15 Hologic
  • 10.2.16 Revvity Inc
  • 10.2.17 Fujirebio Holdings
  • 10.2.18 Mylab Discovery Solutions